Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Paroxysmal Dyskinesia and Synaptic Transmission Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PNKD drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PNKD Recombinant Protein (WT & A7V/A9V Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PNKD Products |
| Gene Delivery | PNKD Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PNKD Products |
| Benchmark Ab | Anti-PNKD Recombinant Antibody Recombinant positive control. |
View PNKD Products |
| Validator | PNKD siRNA Set For knockdown verification. |
View PNKD Products |
| Related Target A | RIMS1 Scaffolding protein interacting with PNKD to modulate synaptic vesicle exocytosis. |
View RIMS1 Products |
| Related Target B | ADORA2A Adenosine A2A receptor; critical in caffeine-induced dyskinesia pathways linked to PNKD. |
View ADORA2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform-specific targeting (PNKD-L vs PNKD-S) | Isoform-specific sequence-verified clones and recombinant proteins available |
| Disease mutant verification (A7V, A9V) | Custom mutant proteins and Lentiviral particles strictly verified by Sanger sequencing |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PNKD R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PNKD therapeutics is intensifying, with major players shifting focus from traditional mAbs to gene therapies and small molecule synaptic modulators. As first-generation therapies reach the clinic, the next wave of R&D is targeting isoform-specific interactions and genetic correction of pathogenic mutations.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV/Lentivirus) | Academic Medical Centers, Neuro-Biotechs | Paroxysmal Nonkinesigenic Dyskinesia | Expression validation (Need sequence-verified Lentivirus) |
| Small Molecule | Neurology-focused Pharma | Movement Disorders, Synaptic Dysfunction | Selectivity Assay (Need Mutant vs WT Proteins) |
| RNAi / Antisense | RNA Therapeutics Specialists | Gain-of-Function Myoclonus/Dyskinesia | Knockdown validation (Need validated siRNA) |